Cytosorbents CorpCTSO

Cytosorbents Corp’s latest 10-Q, filed for the quarter ended 31 March 2026, shows a net loss attributable to the parent of $5.1 million, an operating loss of $3.0 million, and shareholders’ equity of just $2.2 million against liabilities of $38.4 million. The company burned $1.2 million of operating cash during the period and ended the quarter with $4.8 million in cash and cash equivalents-enough to fund roughly two more quarters of the current burn if no revenue arrives. Diluted loss per share came in at $-0.08 on 62.7 million diluted shares, a share-count that has been marching steadily upward while the balance sheet marches in the opposite direction.

Cytosorbents is a clinical-stage company building blood-purification devices centred on its proprietary hemoadsorption technology, marketed under the CytoSorb brand. The company’s website presents a product array “strategically crafted to restore vital balance across diverse fields of application,” which in practice means single-use polymer columns designed to adsorb cytokines, bilirubin, myoglobin, and other small-molecule toxins from whole blood in extracorporeal circuits. Its lead investigational system, DrugSorb™-ATR, is an antithrombotic removal platform intended to complement CytoSorb columns, but the filing explicitly labels it “an investigational device based on an equivalent polymer,” a phrasing that stops short of claiming any revenue-generating clearance or approval.

The company’s filing universe for the quarter includes a 10-Q that reports $4.5 million of inventory net, a $723 k reduction in inventories, $1.0 million of R&D expense, and capitalised capex of just $11 k. Board oversight is formalised in a written charter accessible on the company website, and the board has adopted written policies for reviewing related-party transactions-standard housekeeping when cash is scarce and the next financing round is not yet priced. The June DEF 14A also discloses the board’s governance framework, yet none of the filings or product pages provide audited revenue, gross margin, or customer order book data that would answer the obvious question: how does CytoSorbents expect to convert its technology into sales?

If you want to see the stock price in context, TradingView’s daily chart under ticker CTSO shows the equity still trading below $0.70 as of 25 July 2026, down from peaks above $3 in 2021. The chart itself is just a market mechanism; it does not explain why the company has not yet demonstrated a sustained path to profitability or positive operating cash flow.

What changed this week: nothing in the filings alters the fundamentals. The SEC archive simply confirms the ongoing disclosure rhythm-quarterly 10-Qs, periodic 8-Ks, and an annual DEF 14A-with no surprises beyond the familiar drumbeat of losses and share dilution. The company’s 8-K on 6 July 2026 notes routine updates; the 25 June 2026 DEF 14A and DEFA14A contain governance boilerplate and reminders that the board charter and related-party policies are available on the website. The product pages remain aspirational, offering high-resolution images of adsorption columns and “solutions” slides that do not include unit volumes, reimbursement codes, or named hospital contracts.

What remains unproven: audited revenue, positive operating cash flow, gross margin, clinical adoption data, regulatory approvals beyond the existing EU/CE marks, and any concrete evidence that DrugSorb™-ATR has generated commercial sales. The evidence supplied does not include any FDA 510(k) clearance announcements, CMS reimbursement decisions, or peer-reviewed studies showing mortality or morbidity benefit versus standard care. Until those are filed, the narrative gap between the polished platform and the balance sheet remains a feature, not a bug.

What would change the file next: a quarterly 10-Q showing positive operating income, positive operating cash flow, or a tangible revenue line above zero; a new 510(k) clearance or CE mark expansion; FDA approval or CMS reimbursement for DrugSorb™-ATR or a CytoSorb column; or an 8-K announcing a customer contract with named hospitals and material revenue recognition. Short of that, investors will continue to rely on the same disclosures that have already told the story: losses, dilution, and a balance sheet too thin to fund the runway beyond early 2027.